Skip to main content

Novus Biologicals products are now on bio-techne.com

Better as one

Recombinant Human VEGF 165 Protein

Bio-Techne includes R&D Systems | Catalog # 293-VE

Catalog #
Availability
Size / Price
Qty
Loading...
Carrier Free
293-VE-001MG/CF
293-VE-010/CF
Show More Sizes
293-VE-050/CF
293-VE-500/CF
Show Fewer Sizes

Catalog #
Availability
Size / Price
Qty
With Carrier
293-VE-010
293-VE-01M
Show More Sizes
293-VE-050
293-VE-500
Show Fewer Sizes

Key Product Details

Source

Sf 21 (baculovirus)

Accession #

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Spodoptera frugiperda, Sf 21 (baculovirus)-derived human VEGF protein
Ala27-Arg191

Purity

>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala27

Predicted Molecular Mass

19.2 kDa (monomer)

SDS-PAGE

20-22 kDa, under reducing conditions.
39-42 kDa, under non-reducing conditions.

Activity

Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1323.
The ED50 for this effect is 1-6 ng/mL.

Scientific Data Images for Recombinant Human VEGF 165 Protein

Recombinant Human VEGF 165 Protein Bioactivity

Recombinant Human VEGF 165 Protein Bioactivity

Recombinant Human VEGF165(Catalog # 293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells. The ED50 is 1-6 ng/mL.

Recombinant Human VEGF 165 Protein Bioactivity Comparison.

As an alternative, please consider our next generation Recombinant Human VEGF 165 (Catalog # BT-VEGF). It has equivalent bioactivity to Recombinant Human VEGF 165 (Catalog # 293-VE). It combines R&D Systems quality with scalability that allows for a solid supply chain. Both Recombinant Human VEGF 165 proteins are measured in a cell proliferation assay using HUVEChuman umbilical vein endothelial cells.
Recombinant Human VEGF 165 Protein SDS-PAGE

Recombinant Human VEGF 165 Protein SDS-PAGE

1 μg/lane of Recombinant Human VEGF165was resolved by SDS-PAGE with silver staining, under reducing (R) and non-reducing (NR) conditions, showing major bands at 20-22 kDa and 39-42 kDa, respectively. Multiple bands in gel are due to glycosylation.

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 293-VE
Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin. Alternatively, reconstitute at 100‑500 μg/mL in sterile 4 mM HCl containing 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Carrier Free: 293-VE/CF
Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with trehalose.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS. Alternatively, reconstitute at 100-500 μg/mL in sterile 4 mM HCl.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGF

Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult (1-3). It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues and a cystine knot structure (4). Humans express alternately spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (aa) in length (4). VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189 (3, 4). Isoforms other than VEGF121 contain basic heparin-binding regions and are not freely diffusible (4). Human VEGF165 shares 88% aa sequence identity with corresponding regions of mouse and rat, 96% with porcine, 95% with canine, and 93% with feline, equine and bovine VEGF, respectively. VEGF binds the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) on endothelial cells (4). Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity (3, 4). VEGF165 binds the semaphorin receptor, Neuropilin-1 and promotes complex formation with VEGF R2 (5). VEGF is required during embryogenesis to regulate the proliferation, migration, and survival of endothelial cells (3, 4). In adults, VEGF functions mainly in wound healing and the female reproductive cycle (3). Pathologically, it is involved in tumor angiogenesis and vascular leakage (6, 7). Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (8). VEGF is induced by hypoxia and cytokines such as IL-1, IL-6, IL-8, oncostatin M and TNF-alpha (3, 4, 9).

Due to its role in angiogenesis of blood vessels, tumor and stroma cells use VEGF to stimulate formation of blood vessels and the proliferation and survival of endothelial cells. Specific immunotherapies targeting the VEGF signaling pathway include the recombinant antibody against VEGF (Bevacizumab), antibodies targeting the main VEGF receptor (VEGFR2), and small molecule inhibitors against VEGF receptor tyrosine kinases (10). Immune checkpoint inhibitors are an important tool in cancer therapies as tumor cells can hijack immune checkpoint signals to evade detection by immune cells. In addition to stimulating the formation of tumor blood vessels, VEGF has immunosuppressive effects by acting on dendritic cells to block their antigen-presenting and T cell stimulatory functions. Targeting VEGF in combination with other immune checkpoint ligands or receptors may prove more effective in immunotherapy approaches to certain cancer types (11). Because of its role in the formation of blood vessels, VEGF is also an important factor in skeletal development where blood supply and vascularization are crucial. This has made VEGF an important molecule in regenerative studies for bone repair as sustained release of VEGF has been shown to improve the efficiency of bone regeneration (12).

In differentiation protocols for stems cells, VEGF is a commonly added growth factor for the transformation of induced pluripotent stem cells into hematopoietic progenitor cells used to make Natural Killer cells (13, 14). VEGF has also been used to transform intermediate mesoderm into kidney glomerular podocytes or stem cell-derived liver spheres (15, 16). VEGF may also be used in assistance of stem cell transplantations by supporting angiogenesis at sites of stem cell transplants or as a honing tool for adipose-derived mesenchymal stem cells or bone marrow stem cells to migrate to (17, 18).

References

  1. Leung, D.W. et al. (1989) Science 246:1306.
  2. Keck, P.J. et al. (1989) Science 246:1309.
  3. Byrne, A.M. et al. (2005) J. Cell. Mol. Med. 9:777.
  4. Robinson, C.J. and S.E. Stringer (2001) J. Cell. Sci. 114:853.
  5. Pan, Q. et al. (2007) J. Biol. Chem. 282:24049.
  6. Weis, S.M. and D.A. Cheresh (2005) Nature 437:497.
  7. Thurston, G. (2002) J. Anat. 200:575.
  8. Carvalho, J.F. et al. (2007) J. Clin. Immunol. 27:246.
  9. Angelo, L.S. and R. Kurzrock (2007) Clin. Cancer Res. 13:2825.
  10. Apte, R.S. et al. (2019) Cell 176(6):1248.
  11. Sangro, B. et al. (2021) Nature 18:525-543.
  12. Hu, K. & Olsen, B.R. (2016) Bone 91:30-38.
  13. Zhou, Y. et al. (2022) Cancers 14:2266.
  14. Li, Y. et al. (2018) Cell Stem Cell 23(2):181-192.
  15. Musah, S. et al. (2018) Nat. Protoc. 13(7):1662-1685.
  16. Meseguer-Ripolles, J. et al. (2021) STAR Protoc. 2(2):100502.
  17. Hutchings, G. et al. (2020) Int. J. Mol. Sci. 21(11):3790.
  18. Zhang, W. et al. (2014) Euro Cell and Mater. 27:1-12.

Long Name

Vascular Endothelial Growth Factor

Alternate Names

MVCD1, VAS, Vasculotropin, VEGF-A, VEGFA, VPF

Entrez Gene IDs

7422 (Human); 22339 (Mouse); 83785 (Rat); 281572 (Bovine); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)

Gene Symbol

VEGFA

UniProt

Additional VEGF Products

Product Documents for Recombinant Human VEGF 165 Protein

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human VEGF 165 Protein

For research use only

Citations for Recombinant Human VEGF 165 Protein (435)

Showing  1 - 10 of 435 publications Showing All
Filter By:
Search Title:

Citations are publications that use Bio-Techne products. Selected citations for Recombinant Human VEGF 165 Protein include:

There are no citations that match your criteria.

Showing  1 - 10 of 435 publications Showing All

Customer Reviews for Recombinant Human VEGF 165 Protein (29)

4.8 out of 5
29 customer ratings
5 stars
83%
4 stars
17%
3 stars
0%
2 stars
0%
1 star
0%

Customer Images


Showing  1 - 5 of 29 reviews Showing All
Filter By:
  • Recombinant Human VEGF 165 Protein
    Name: Anonymous
    Application: Stem/Immune cell maintenance or differentiation
    Verified Customer | Posted 09/27/2023
    Recombinant Human VEGF 165 Protein 293-VE
  • Recombinant Human VEGF 165 Protein
    Name: Anonymous
    Application: Cell migration/motility
    Verified Customer | Posted 03/18/2021
    The experiment was aimed to test the effect of human VEGFA in EC migration by scratch wound migration assay.
    Recombinant Human VEGF 165 Protein 293-VE
  • Recombinant Human VEGF 165 Protein
    Name: Anonymous
    Application: Immunoassay Standard
    Verified Customer | Posted 02/05/2021
    Nice result
  • Recombinant Human VEGF 165 Protein
    Name: Anonymous
    Application: Stem/Immune cell maintenance or differentiation
    Verified Customer | Posted 10/13/2020
    Recombinant Human VEGF 165 Protein 293-VE
  • Recombinant Human VEGF 165 Protein
    Name: Anonymous
    Application: Stem/Immune cell maintenance or differentiation
    Verified Customer | Posted 10/13/2020
  • Recombinant Human VEGF 165 Protein
    Name: Anonymous
    Application: Binding assay/Protein-protein interaction
    Verified Customer | Posted 08/02/2020
    Recombinant Human VEGF 165 Protein 293-VE
  • Recombinant Human VEGF 165 Protein
    Name: Anonymous
    Application: Cell migration/motility
    Verified Customer | Posted 12/10/2018
  • Recombinant Human VEGF 165 Protein
    Name: Zoia Levashova
    Application: Immunoassay Standard
    Verified Customer | Posted 11/26/2018
    The recombinant human VEGF protein was used as the calibration reagent in MSD assay with biotinylated MAB293 (capture) and Sulfo-Tag labeled AF-293-NA (detection) antibodies.
    Recombinant Human VEGF 165 Protein 293-VE